Trials / Terminated
TerminatedNCT02342353
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of the study is to find the best dose of pacritinib when given in combination with erlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pacritinib | |
| DRUG | Erlotinib |
Timeline
- Start date
- 2015-05-18
- Primary completion
- 2018-02-06
- Completion
- 2018-02-06
- First posted
- 2015-01-19
- Last updated
- 2018-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02342353. Inclusion in this directory is not an endorsement.